CorMedix Inc. Files 8-K on Officer Changes and Shareholder Votes

TL;DR

CorMedix 8-K: Exec changes, director elections, shareholder votes, and financials filed Nov 21.

AI Summary

CorMedix Inc. filed an 8-K on November 21, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits. Specific details regarding names, dollar amounts, and dates of these events are not provided in the excerpt.

Why It Matters

This filing indicates significant corporate governance and potential executive changes at CorMedix Inc., which could impact the company's strategic direction and investor confidence.

Risk Assessment

Risk Level: medium — The filing pertains to corporate governance and executive appointments, which can signal shifts in company strategy or stability.

Key Players & Entities

• CorMedix Inc. (company) — Registrant
• November 21, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common stock, $0.001 par value CRMD Nasdaq Global Market

Filing Documents

• ea0222389-8k_cormedix.htm (8-K) — 38KB
• 0001213900-24-102170.txt ( ) — 209KB
• crmd-20241121.xsd (EX-101.SCH) — 3KB
• crmd-20241121_lab.xml (EX-101.LAB) — 33KB
• crmd-20241121_pre.xml (EX-101.PRE) — 22KB
• ea0222389-8k_cormedix_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held the 2024 Annual Meeting virtually on November 21, 2024 at 9:00 a.m., Easter Time. Holders of shares of the Company's common stock, Series E Preferred Stock and Series G Preferred Stock were entitled to vote at the 2024 Annual Meeting. The Company's stockholders voted on the following four proposals at the Annual Meeting, casting their votes as described below. For more information about the following proposals, please see the Proxy Statement. Proposal No. 1 - Election of Directors . The following individuals, each of whom was named as a nominee in the Proxy Statement, were elected by the Company's stockholders by a plurality of votes cast to serve on the Company's board of directors until the Company's 2025 annual meeting of stockholders. Information on the vote relating to each director standing for election is set forth below: Nominee FOR WITHHELD BROKER NON-VOTES Janet Dillione 17,928,669 2,212,986 20,924,754 Gregory Duncan 19,823,680 317,975 20,924,754 Alan W. Dunton 19,484,920 656,735 20,924,754 Myron Kaplan 15,871,681 4,269,974 20,924,754 Steven Lefkowitz 19,894,076 247,579 20,924,754 Robert Stewart 18,514,483 1,627,172 20,924,754 Joseph Todisco 19,963,389 178,266 20,924,754 Proposal No. 2 - Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers for 2023 . Proposal No. 2 was to approve, on a non-binding advisory basis, the compensation paid to the Company's named executive officers for 2023, as disclosed in the Proxy Statement. The proposal was approved. The results of the vote taken were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 17,510,538 2,400,036 231,081 20,924,754 Proposal No. 3 - Approval of Amendment to the Amended and Restated 2019 Omnibus Stock Incentive Plan . Proposal No. 3 was to approve an amendment to the Amended and Restated 2019 Omnibus Stock Incentive Plan to increase t

View Full Filing

View this 8-K filing on SEC EDGAR